Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2087-2092

  Liu, Tiancheng ^a   Wu, Lisa Y ^a   Fulton, Melody D ^a   Johnson, Jacqueline M ^a   Berkman, Clifford E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Androgen deprivation; Androgen receptor; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

AFFINITY LABELING; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANDROGENS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84869826414     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1649     Document Type: Article

References (39)

1. Gustavsson H, Welen K and Damber JE: Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364-373, 2005. (Pubitemid 40227488)
2. Niu Y, Altuwaijri S, Lai KP, et al: Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 105: 12182-12187, 2008.
3. Davis JN, Wojno KJ, Daignault S, et al: Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 66: 11897-11906, 2006. (Pubitemid 46094202)
4. Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H and Gao AC: Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate 67: 1293-1300, 2007. (Pubitemid 47435777)
5. Saraon P, Jarvi K and Diamandis EP: Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 57: 1366-1375, 2011.
6. Devlin HL and Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186, 2009.
7. Watson PA, Chen YF, Balbas MD, et al: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107: 16759-16765, 2010.
8. Yuan TC, Veeramani S, Lin FF, et al: Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13: 151-167, 2006.
9. Zhang K and Waxman DJ: PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer 9: 319, 2010.
10. Bae KM, Su Z, Frye C, et al: Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 183: 2045-2053, 2010.
11. Rajasekaran AK, Anilkumar G and Christiansen JJ: Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 288: C975-C981, 2005. (Pubitemid 40559373)
12. Lee SJ, Lee K, Yang X, et al: NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen. J Mol Biol 330: 749-760, 2003.
13. Ghosh A and Heston WD: Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91: 528-539, 2004.
14. Israeli RS, Powell CT, Corr JG, Fair WR and Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994. (Pubitemid 24116191)
15. Liu T, Wu LY, Hopkins MR, Choi JK and Berkman CE: A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 20: 7124-7126, 2010.
16. Matroule JY, Carthy CM, Granville DJ, Jolois O, Hunt DW and Piette J: Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene 20: 4070-4084, 2001. (Pubitemid 32681612)
17. Liu T, Wu LY and Berkman CE: Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett 296: 106-112, 2010.
18. Liu T, Toriyabe Y and Berkman CE: Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 49: 251-255, 2006. (Pubitemid 44416227)
19. Liu T, Wu LY, Kazak M and Berkman CE: Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68: 955-964, 2008. (Pubitemid 351794160)
20. Wu LY, Anderson MO, Toriyabe Y, et al: The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 15: 7434-7443, 2007. (Pubitemid 47539133)
21. Anderson MO, Wu LY, Santiago NM, et al: Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 15: 6678-6686, 2007. (Pubitemid 47385247)
22. Maung J, Mallari JP, Girtsman TA, et al: Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 12: 4969-4979, 2004. (Pubitemid 39164405)
23. Wolf DA, Herzinger T, Hermeking H, Blaschke D and Horz W: Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol Endocrinol 7: 924-936, 1993. (Pubitemid 23220643)
24. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ and Chang C: Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 29: 3593-3604, 2010.
25. Ross JS, Sheehan CE, Fisher HA, et al: Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9: 6357-6362, 2003. (Pubitemid 38031820)
26. Perner S, Hofer MD, Kim R, et al: Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38: 696-701, 2007. (Pubitemid 46560805)
27. Kokontis JM, Hay N and Liao S: Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953, 1998. (Pubitemid 30660662)
28. Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N and Aoki Y: Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate 70: 457-466, 2010.
29. Suzuki H, Ueda T, Ichikawa T and Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10: 209-216, 2003. (Pubitemid 36758650)
30. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI and Oyasu R: Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47: 66-75, 2001. (Pubitemid 32246754)
31. Mhawech-Fauceglia P, Smiraglia DJ, Bshara W, et al: Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer Epidemiol Biomarkers Prev 17: 571-577, 2008. (Pubitemid 351469206)
32. Ghosh A, Wang X, Klein E and Heston WD: Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res 65: 727-731, 2005. (Pubitemid 40216430)
33. Tang Y, Hamburger AW, Wang L, Khan MA and Hussain A: Androgen deprivation and stem cell markers in prostate cancers. Int J Clin Exp Pathol 3: 128-138, 2009.
34. Ghosh A and Heston WD: Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate 57: 140-151, 2003. (Pubitemid 37204495)
35. Holmes EH, Greene TG, Tino WT, et al: Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate (Suppl) 7: 25-29, 1996. (Pubitemid 26412173)
36. Barinka C, Sacha P, Sklenar J, et al: Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 13: 1627-1635, 2004. (Pubitemid 38669250)
37. Luthi-Carter R, Barczak AK, Speno H and Coyle JT: Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Res 795: 341-348, 1998. (Pubitemid 28337848)
38. Tiffany CW, Lapidus RG, Merion A, Calvin DC and Slusher BS: Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate 39: 28-35, 1999. (Pubitemid 29143106)
39. Luthi-Carter R, Barczak AK, Speno H and Coyle JT: Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 286: 1020-1025, 1998. (Pubitemid 29003499)